DOCSLIB.ORG

B Ramamohima R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B Ramamohima R I I CYTOPROTECTIVE ACTIONS PF NICOTINE: THE INCREASED EXPRESSION OF a.7 NICOTINIC RECEPTORS AND NGF/TrkA RECEPTORS ' . ' f !'b y' Ramamohima R. Jonnala ' ' ' I' Submitted to the Faculty o~the School of Graduate Studies of Medical College of Georgia in Partial Fulfillment of the Requirements of the Degree of Doctor of Philosophy Juiy, 2001 I' l Cytoprotective Actions of Nicotine: The Increased Expression of a.7 Nicotinic Receptors a-!ld NGF/TrkA Receptors This dissertation is submitted by Ramamohana R. Jonnala and has been examined and approved by an appointed committee of the faculty of the school of Graduate Studies of the Medical College of Georgia. The signatures which appear below verify the fact that all required changes have been incorporated and that the dissertation has received final approval with reference to content, form and accuracy of presentation. ' This dissertation is therefore in partial fulfillment of the requirements of the degree of Doctor of Philosophy. ACKNOWLEDGMENTS I would like to extend my appreciation to my major advisor, Dr. Jerry J. Buccafusco, for his guidance, encouragement and support. I would also like to thank my committee members, Dr. Alvin V. Terry Jr., Dr. William D. Hill, Dr. Nevin A. Lambert and Dr. Clare M. Bergson and also my thesis readers Dr. Debra Gearhart and Dr. Dale W. Sickles for their time and valuable suggestions. My sincere thanks to Dr. Deborah L. Lewis, Dr. Robert W. Caldwell and Dr. Gary C. Bond for encouraging me to enter the graduate program in the Department of Pharmacology & Toxicology, Medical College of Georgia. My sincere thanks to members of my laboratory Laura, Vanessa, Daniel, Cat, Mark, Nandu, Lu, and Shyamala for their assistance and suggestions. TABLE OF; CONTENTS Page ABSTACT ............................................................. : ............ .. lll LIST OF FIGURES ................................................................ .. vii LIST OF TABLES ................................................................. .. ix LIST OF ABBREVATIONS ..................................................... .. X I. INTRODUCTION A. Significance of study ............... ,..................................... 1 B. Literature review ........................................................ .. 3 I. Alzheierm's disease pathophysiology .......................... 3 2. Genetics of AD ...................................................... 6 3. The selective vulnerability ofBFC neurons .................... 7 4. NGF and NGF receptors ........................................ .. 9 5. Oxidative damage .................................................. 10 6. Cholinomimetic therapy ........................................ .. 12 7. N1cotmic receptors .............................................. .. 14 8. The PC12 cell model system .................................... .. 18 II. MATERIALS AND METHODS Cell culture ................................................................. .. 21 Compounds ................................................................ .. 21 Strucutres of choline and choline analogs .............................. .. 22 Cell vi;;tbility assay ......................................................... 23 125 [ I]a-BGT binding assay ...................................... : ........ .. 23 Elisa assay ..................................................................... 24 Animals ....................................................................... 25 Surgical procedure .......................................................... 25 Westemblot.................................................................. 25 Exposure of PC12 cells peroxynitrite ................................... .. 26 Cytosensor Microphysiometer ............................................ 27 Cell lysate preparation ..................................................... 27 Immunoprec1p1 . ·1at1· on s tudi es ............................................... 28 MAPKassay............................................................... .. 29 Page I.RESULTS I. Stimulation of cx7nAChR protects differentiated PC12 cells from trophic factor withdrawal toxicity. .. 3 0 2. Neuroprotective actions of cholii1e·and choline analogs............ 31 3. The abilities of different nAChR agonists to indµce neuroprotection.. .. .. .. .. .. .. 32 4. The abilities of different nAChR agonists to induce cx7nAChR upregulation............................................................... 33 5. MLA induced increase in cx7nAChR expression and neuroprotection... .. .. .. .. .. .. .. .. .. 34 6. Nicotine up-regulates TrkA receptors................................. 35 7. Relationship between nicotine's neuroprotection and its ability to increase TrkA receptors ............... :................................ 37 8. Metabolic response of PC12 cells to NGF............................ 38 9. Effect of SIN-I on cell viability........................................ 39 10. Inhibition ofNGF mediated metabolic responses by SIN-1...... .. 40 11. Effects of SIN-I on TrkA receptor autophosphorylation.. ..... .. .. 40 12. Effects of SIN-1 on MAPK activity.................................... 41 IV. DISCUSSION I. Neuroprotective actions of nicotine..................................... 42 2. Choline and Choline analogs............................................. 45 3. Relationship between the ability to produce neuroprotection and the upregulation of cx7nAChRs. ... .. .. .. .... 47 4. Relationship between increased TrkA receptors and neuroprotection.. 51 5. Importance ofNGF signaling............................................. 54 V. SUMMARY.......................................................................... 61 VI. REFERENCES....................................................................... 89 Abstract: Certain epidemiological studies have reported a negative correlation between smoking and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease, reflecting perhaps the neurotrophic actions of nicotine. In recent years there has been intense interest in the development° of new nicotinic acetylcholine receptor (nAChR) agonists. These agents have the potential to be used in the treatment of patients with AD. However, the mechanism for the neuroprotective action of the nicotine is not yet known, indeed, it is not yet clear as to which subtype of nAChR mediates the response. In neuronal cell lines, the induction of cytoprotection often requires exposure to nicotine for up to 24 hr to produce a full neuroprotective effect and this chronic exposure of nicotine is also known to increase nAChR receptors and cell surface nerve growth factor (NGF) receptors. The purpose of this study is to determine which subtype of nAChRs are involved in nicotine's neuroprotective actions and also to determine whether nicotine's neuroprotective actions are related to its ability to increase cell surface nAChRs and NGF receptors. Preincubation of differentiated PC 12 _cells with nicotine for 24 hr protected the cells from growth factor withdrawal-induced toxicity in a time and concentration-dependent manner. Nicotine's cytoprotective actions were completely blocked oy non-selective nAChR antagonist mecarnylarnine, and the a7nAChR preferring antagonist methyllcaconitine (MLA) indicating that the response was primarily mediated by the subtype of a7 nAChR receptors. The acetylcholine precursor, choline is a very selective 111 and full agonist at a.7 receptors. Among five choline analogs tested for neuroprotection potential, acetylpyrrolidinecholine and pyrrolidinecholine were found to be more potent and more efficacious than their parent co_mpound, choline. The rank order of the six compounds tested for their cytoprotective ability is as follows: acetylpyrrolidinecholine = pyrrolidinecholine · > choline = monoethylcholine = diethylcholine = triethylcholine. Further, to confirm the above structure activity relationships with respect to their binding affinities at u7nAChR, [1 25I]u-bungarotoxin (BGT) displacement binding studies were performed using differentiated PC12 cells. Choline was only 50 fold less potent than nicotine in displacing [125I]u-BGT binding. Pyrrolidinecholine, the most active analog, fully displaced [125I]u-BGT binding and it exhibited a slightly greater affinity for the site than did choline. Next we compared the ability of seven different nAChR agonists with varying activities at a.7 receptors for their ability to produce cytoprotection. Among the seven compounds tested, nicotine was the most effective and the most potent followed in order of potency by 4OH-GTS21, epibatidine, methylcarbamylcholine, 1, 1-Dimethyl-4-phenyl-piperazinum, cytisine and tetraethylarnmonium. Since, epibatidine and cytisine were less efficacious than nicotine despite their greater affinity for a.7 receptors and because short-term exposure of cells to nicotine did not produce cytoprotective actions, we next compared the ability of these compounds to upregulate cell surface a.7 receptors. After, incubation of cells for 2 hr with either nicotine or cytisine, the number of [1 25I]u-BGT binding sites on differentiated PC12 cells were measured. Nicotine, the most efficacious compound increased the [125I]u­ BGT binding sites by ~40% over the untreated control cells. In contrast, cytisine, the least effective compound failed to do so, indicating that the ability to upregulate a.7 receptors iv may provide one possible mechanism for neuroprotective actions of nicotine. Further, we confirmed that these additional populations of receptors were
Load more

Recommended publications
  • Downloaded for Personal Non-Commercial Research Or Study, Without Prior Permission Or Charge
    https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] STUDIES OU THE MODE OF ACTION OF QUATERNARY AMMONIUM COMPOUNDS WITH MUSCLE RELAXANT AND OTHER PHARMACOLOGICAL ACTIVITIES A Thesis submitted to the University of Glasgow in candidature for the degree of Doctor of Philosophy in the Faculty of Medicine *y Thomas C. Muir, B.Sc., M.P.S. Division of Experimental Pharmacology, Institute of Physiology, The University, Glasgow. March 1962. ProQuest Number: 10656287 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10656287 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
    [Show full text]
  • Journal of Pharmacy and Pharmacology 1962 Volume.14 Suppl
    BRITISH PHARMACEUTICAL CONFERENCE NINETY-NINTH ANNUAL MEETING, LIVERPOOL, 1962 REPORT OF PROCEEDINGS OFFICERS: President: Miss M. A. Bu rr, M.P.S., Nottingham Chairman: J. C. H anbury, M.A., B.Pharm., F.P.S., F.R.I.C. Vice-Chairmen: R. R . Bennett, B.Sc., F.P.S., F.R.I.C., Eastbourne. H . D eane, B.Sc., F.P.S., F.R.I.C., Sudbury. H . H umphreys Jones, F.P.S., F.R.I.C., Liverpool. T. E. W allis, D .S c., F.P.S., F.R.I.C., F.L.S., London. H . Brindle, M .Sc., F.P.S., F.R.I.C., Altrincham. N. Evers, B.Sc., Ph.D., F.R.I.C., Ware. A. D . P ow ell, M.P.S., F.R.I.C., Nottingham. H. Berry, B.Sc., Dip.Bact. (Lond.), F.P.S., F.R.I.C., Eastbourne. H . B. M ackie, B.Pharm., F.P.S., Brighton. G. R. Boyes, L.M.S.S.A., B.Sc., F.P.S., F.R.I.C., London. H . D avis, C.B.E., B.Sc., Ph.D., F.P.S., F.R.I.C., London. J. P. T o dd , Ph.D., F.P.S., F.R.I.C., Glasgow. K. Bullock, M .Sc., Ph.D., F.P.S., F.R.I.C., Manchester. F. H artley, B.Sc., Ph.D., F.P.S., F.R.I.C., London. G. E. F oster, B.Sc., Ph.D., F.R.I.C., Dartford. H . T reves Bro w n , B.Sc., F.P.S., London.
    [Show full text]
  • INTRODUCTION One of the Tasks of a Pharmacologist Is the Classification of Drugs
    NEUROPSYCHOPHARMACOLOGIC STUDIES OF MARIJUANA: SOME SYNTHETIC AND NATURAL THC DERIVATIVES IN ANIMALS AND MAN* Edward F. Domino Department of Pharmacology, University of Michigan, Ann Arbor 48104 and Lafayette Clinic, Detroit, Mich. 48207 INTRODUCTION One of the tasks of a pharmacologist is the classification of drugs. Marijuana and its derivatives pose some problems. Legally marijuana has been classified as a narcotic, yet pharmacologically it is quite different. Mankind has known about the Cannabis plant from which marijuana and other products are obtained for more than 4,708 years. A considerable body of data is available to describe its gross effects. Over the centuries it has been called a depressant, euphoriant, ine- briant, intoxicant, hallucinogen, psychotomimetic, sedative-hypnotic-anesthetic, and stimulant. Perhaps more than any other drug it is a social irritant that elicits rather remarkable behavior reactions in both users and nonusers. Moreau’ in 1845, employed it to produce a model psychosis, thus initiating the fashion to study hallucinogens as a means of gaining insights into mental illness. Lewin2 classified Cannabis as one of the “phantastica: hallucinating substances.” One text on hallucinogens3 does not even refer to Cannabis, but another does? There are some aspects of the subjective effects of both LSD-25 and Cannabis that are similar, yet the latter produces sedative effects, no significant sympatho- mimetic actions, and no cross-tolerance to LSD-25. Hollister5 reviewed the re- cent findings on the effects in man of marijuana and its putative active ingredient Ag-THC, stressing that current investigators have, for the most part, confirmed the Cannabis-induced clinical syndromes long known to occur.
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • An Analysis of the Facilitatory Action of Catechol and Phenol at the Neuromuscular Junction of the Cat
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 1972 An Analysis of the Facilitatory Action of Catechol and Phenol at the Neuromuscular Junction of the Cat Joel P. Gallagher Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Medicine and Health Sciences Commons Recommended Citation Gallagher, Joel P., "An Analysis of the Facilitatory Action of Catechol and Phenol at the Neuromuscular Junction of the Cat" (1972). Dissertations. 1138. https://ecommons.luc.edu/luc_diss/1138 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1972 Joel P. Gallagher AN ANALYSIS OF THE FACILITATOHY ACTION OF CATECHOL AND PHENOL ·AT THE NEUROMUSCULAR JUNCTION OF THE CAT .A dissertation presented by Joel P. Gallagher for ihe dcg:~ee of DOCTOR OF PHILOSOPHY at the DF.~PARTMENT OF PHARMACOLOGY LOYOLA UNPlERSITY MEDIC.!\L CENTER MAYWOOD, ILLI:;:~OIS F'ebru8.ry, Hl72 lOYOlA ll!RARY UNIViR.SiTY MEDIC "I. "" CENTER ..-------------~----..a"!..... --·-·-·-·--·----~..-----------------------,._,_...,.... ........ __________ -:"I BIOGRAPHY Joel P. Gallagher was born on December 12, 1942, in Chicago, Illinois. In June of 1960 he graduated from Fenwick High School, Oak Park. The following Fall he began his undergraduate training at the College of St. Thomas. St. Paul, Minnesota where he received the Bachelor of II Science degree in Biology-Chemistry in June 1964.
    [Show full text]
  • Akhtar Saeed Medical and Dental College, Lhr
    STUDY GUIDE PHARMACOLOGY 3RD YEAR MBBS 2021 AKHTAR SAEED MEDICAL AND DENTAL COLLEGE, LHR 1 Table of contents s.No Topic Page No 1. Brief introduction about study guide 03 2. Study guide about amdc pharmacology 04 3. Learning objectives at the end of each topic 05-21 4. Pharmacology classifications 22-59 5. General pharmacology definitions 60-68 6. Brief introduction about FB PAGE AND GROUP 69-70 7. ACADEMIC CALENDER (session wise) 72 2 Department of pharmacology STUDY GUIDE? It is an aid to: • Inform students how student learnIng program of academIc sessIon has been organized • help students organIze and manage theIr studIes throughout the session • guIde students on assessment methods, rules and regulatIons THE STUDY GUIDE: • communIcates InformatIon on organIzatIon and management of the course • defInes the objectIves whIch are expected to be achIeved at the end of each topic. • IdentIfIes the learning strategies such as lectures, small group teachings, clinical skills, demonstration, tutorial and case based learning that will be implemented to achieve the objectives. • provIdes a lIst of learnIng resources such as books, computer assIsted learning programs, web- links, for students to consult in order to maximize their learning. 3 1. Learning objectives (at the end of each topic) 2. Sources of knowledge: i. Recommended Books 1. Basic and Clinical Pharmacology by Katzung, 13th Ed., Mc Graw-Hill 2. Pharmacology by Champe and Harvey, 2nd Ed., Lippincott Williams & Wilkins ii. CDs of Experimental Pharmacology iii. CDs of PHARMACY PRACTICALS iv. Departmental Library containing reference books & Medical Journals v. GENERAL PHARMACOLOGY DFINITIONS vi. CLASSIFICATIONS OF PHARMACOLOGY vii.
    [Show full text]
  • Ige and Drug Allergy: Antibody Recognition of 'Small' Molecules of Widely Varying Structures and Activities
    Antibodies 2014, 3, 56-91; doi:10.3390/antib3010056 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Review IgE and Drug Allergy: Antibody Recognition of ‘Small’ Molecules of Widely Varying Structures and Activities Brian A. Baldo † Molecular Immunology Unit, Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, and Department of Medicine, University of Sydney, Sydney 2065, Australia; E-Mail: [email protected]; Tel.: +61-2-9880-9757 † Author is retired. Formerly: Head of Molecular Immunology Unit. Received: 19 November 2013; in revised form: 19 December 2013 / Accepted: 18 January 2014 / Published: 22 January 2014 Abstract: The variety of chemically diverse pharmacologically-active compounds administered to patients is large and seemingly forever growing, and, with every new drug released and administered, there is always the potential of an allergic reaction. The most commonly occurring allergic responses to drugs are the type I, or immediate hypersensitivity reactions mediated by IgE antibodies. These reactions may affect a single organ, such as the nasopharynx (allergic rhinitis), eyes (conjunctivitis), mucosa of mouth/throat/tongue (angioedema), bronchopulmonary tissue (asthma), gastrointestinal tract (gastroenteritis) and skin (urticaria, eczema), or multiple organs (anaphylaxis), causing symptoms ranging from minor itching and inflammation to death. It seems that almost every drug is capable of causing an immediate reaction and it is unusual to find a drug that has not provoked an anaphylactic response in at least one patient. These facts alone indicate the extraordinary breadth of recognition of IgE antibodies for drugs ranging from relatively simple structures, for example, aspirin, to complex molecules, such as the macrolide antibiotics composed of a large macrocyclic ring with attached deoxy sugars.
    [Show full text]
  • Amyloid Peptide on Acetylcholine Neurocycle and Alzheimer's Disease Medications
    Pharmacokinetics/Pharmacodynamics and Analysis of the Effect of β- Amyloid Peptide on Acetylcholine Neurocycle and Alzheimer’s Disease Medications by Asmaa Abdallah Awad A thesis presented to the University of Waterloo in fulfillment of the thesis requirement for the degree of Master of Science in Chemical Engineering Waterloo, Ontario, Canada, 2013 ©Asmaa Abdallah Awad 2013 Author's Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii Abstract The brain of Alzheimer’s disease (AD) is characterized by accumulations of β- amyloid peptide aggregates which promote neurodegentartive dysfunction. Comprehensive understanding of the interaction between β-amyloid aggregates and acetylcholine (ACh) neurocycle is required to uncover the physiological processes related to AD and might result in improving therapeutic approaches for AD. Pharmacokinetics (PK) and pharmacodynamics (PD) techniques were applied to allow predicting the extent of the interaction of certain doses of AD drugs and β-amyloid inhibitors and levels of ACh as well. Although many researchers focused on the β-amyloid interactions, the mechanisms by which β-amyloid affects cholinergic neurons and reduction of ACh are still unclear. The prediction of ACh and drug concentrations in the tissues and body needs an understanding of the physiology and mechanisms of β-amyloid aggregates processes and their compilation into a mechanistic model In this work, two hypotheses are proposed to investigate the dynamic behavior of the interaction between β-amyloid peptide aggregates and cholinergic neurocycle and the possible therapeutic approaches through proposing pharmacokinetic/pharmacodynamics (PK/PD) models to represent the impact of β-amyloid aggregates in AD.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • Animal-Related Computer Simulation Programs for Use in Education and Research
    DOCUMENT RESUME ED 365 288 IR 016 460 AUTHOR Engler, Kevin P. TITLE Animal-Related Computer Simulation Programs for Use in Education and Research. AWIC Series Number 1. INSTITUTION National Agricultural Library, Beltsville, MD. PUB DATE Dec 89 NOTE 58p.; Produced by the Animal Welfare Information Center. PUB TYPE Reference Materials Directories/Catalogs (132) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS Anatomy; *Animal Husbandry; Animals; Annotated Bibliographies; Biochemistry; *Biological Sciences; Computer Assisted Instruction; *Computer Simulation; Computer Software; *Educational Technology; Elementary Secondary Education; Graduate Study; Guides; Higher Education; High Schools; Medical Education; Pharmacology; Physiology; Professional Education; Research Methodology; Research Needs IDENTIFIERS *Computer Models ABSTRACT Computer models have definite limitations regarding the representation of biological systems, but they do have useful applications in reducing the number of animals used to study physiological systems, especially for educational purposes. This guide lists computer models that simulate living systems and can be used to demonstrate physiological, anatomical, pharmacological, and medical concepts. The 48 programs are listed alphabetically and by subject; and an annotated description is given of each, including author, source, price, system requirements, and audience. (SLD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the.original
    [Show full text]
  • THE MOLECULAR MECHANISMS of ORGANOPHOSPHORUS COMPOUND-INDUCED CYTOTOXICITY Kent Richard Carlson
    THE MOLECULAR MECHANISMS OF ORGANOPHOSPHORUS COMPOUND-INDUCED CYTOTOXICITY Kent Richard Carlson Dissertation submitted to the Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Veterinary Medical Sciences Marion Ehrich, Co-Chairperson Bernard S. Jortner, Co-Chairperson Brad Klein Jeff Bloomquist Mitzi Nagarkatti May 19th, 2000 Blacksburg, Virginia Keywords: Organophosphorus, SH-SY5Y, cytotoxicity, apoptosis Copyright 2000, Kent R. Carlson THE MOLECULAR MECHANISMS OF ORGANOPHOSPHORUS COMPOUND-INDUCED CYTOTOXICITY Kent Richard Carlson (ABSTRACT) Certain organophosphorus compounds have the ability to induce a delayed neuropathic condition in sensitive species termed organophosphorus compound-induced delayed neurotoxicity (OPIDN). Esteratic changes associated with OPIDN have been successfully modeled in vitro. The physical characteristics of lesion development in OPIDN including the mode of nerve cell death, cytotoxic initiator and effector molecules, and cytoskeletal involvement have received little in vitro investigation. This dissertation evaluated the mode of cell death (apoptosis versus oncotic-necrosis), and cell cycle, cytoskeletal, nuclear, and mitochondrial alterations induced by OP compounds in SH-SY5Y cultures, an in vitro human neuroblastoma model. The distribution of in vivo neural degeneration in white Leghorn hen models was also assessed as a prelude to validating the mode of OP compound- induced in vivo neural cell death. These endpoints were evaluated by utilizing flow cytometry, spectrophotometry, gel electrophoresis, immunohistochemistry, light, and electron microscopy. Initial data gathered on culture parameters revealed that the mitotic status, basal rates of cell death, and total culture density were dependent on the condition of the media and the initial seeding density.
    [Show full text]
  • Psychotropic Drug Influences on Brain Acetylcholine Utilization*
    Psychopharmacologia (Berl.) 25, 291--298 (1972) by Springer-Verlag 1972 Original Investigations Psychotropic Drug Influences on Brain Acetylcholine Utilization* EDWARD F. DOMINO and ANN E. WILSON Michigan Neuropsychopharmaeology I~eseareh Program, Department of Pharmacology University of Michigan, Ann Arbor, and Lafayette Clinic, Detroit, U.S.A. I~eceived October 6, 1971; Final Version February 14, 1972 Abstract. The cholinergic antisynthesis agent HC-3 was given intraventricularly to young male rats 20--30 days old to deplete brain aeetylcholine (ACh). The rate of ~C-3 induced depletion of ACh was used as an index of ACh utilization. Total brain ACh was determined following various doses of ehlordiazepoxide, pentobarbi- tal, ehlorprom~zine, methotrimeprazine, imipramine, morphine, d-amphetamine, scopolamine, LSD-25, and phencyelidine give~l i.p. alone and after intraventrieular administration of I-IC-3. It was found that psyehotropie drugs have marked differen- tial effects on the rate of I-IC-3 induced ACh depletion. Key words: Acetylcholine -- d-Amphetamine -- Chlordiazepoxide -- Chlor- promazine -- Imipramine -- LSD-25 -- Methotrimeprazine -- Morphine -- Phen- cyclidine -- Psyehotropie Drugs -- Scopolamine. Introduction It is well known that steady state levels of substances in living tissues may not reflect their functional turnover. In autonomic ganglia the pre- ganglionic nerve endings can synthesize acetylcholine (ACh) on demand so that total levels remain the same even during high frequency stimula- tion (Macintosh, 1963). However, in the central nervous system synthesis of ACh cannot keep up with excessive demand. For example, the lowest levels of brain ACh exist during convulsions and the highest during anesthesia (Richter and Crossland, 1949; Crossland and Merriek, 1952).
    [Show full text]